Levofloxacin disk susceptibility test criteria were evaluated by testing 350 bacterial isolates. Either 5-or 10-,ug disks could be used satisfactorily. A 5-,ug levofloxacin disk with zone size breakpoints of .12 mm for resistance (MIC, 28.0 JLg/ml) and .16 mm for susceptibility (MIC, .2 .0 ,ug/ml) is recommended.
Ofloxacin is a fluoroquinolone antimicrobial agent that exists as two optically active isomers because of the asymmetric center at C-3 of the oxazine ring. Levofloxacin (l-ofloxacin) is the more active of the two isomers and has pharmacokinetic properties similar to those of ofloxacin (3, 4, 7, 12, 13) . The spectrum of antibacterial activity of levofloxacin is similar to that of ofloxacin, but levofloxacin is two to four times more potent (2-4, 6, 11, 12) .
The pharmacokinetic properties of levofloxacin in humans are similar to those of ofloxacin, with high concentrations in serum (4.9 ,ug/ml; 350 mg orally), high tissue penetration and a terminal elimination half-life of 6 to 7 h (3, 7, 12) . On the basis of such human pharmacokinetic data, it seems reasonable to characterize bacteria for which the MICs are <2.0 ug/ml as being susceptible and those for which the MICs are >4.0 ,ug/ml as being resistant. These are the tentative MIC breakpoints that have been used for interpreting in vitro test results for ofloxacin and most other fluoroquinolone agents. Such breakpoints should be considered tentative until clinical experience confirms their appropriateness or suggests that modifications need to be made.
To help guide the selection of therapy in patients infected with various gram-negative and gram-positive pathogens, zone size interpretive criteria for disk susceptibility tests are needed. In this report, we describe in vitro studies that were carried out to select the most appropriate disk content for levofloxacin disks and to propose zone size interpretive standards.
Levofloxacin and ofloxacin were provided by Ortho Pharmaceutical Corporation (Raritan, N.J.). Both 5-and 10-,ug levofloxacin disks were prepared at the Clinical Microbiology Institute (Tualatin, Oreg.) to 110% of the stated potency. Agar dilution and disk diffusion susceptibility tests were performed by the procedures recommended by the National Committee for Clinical Laboratory Standards (9, 10). Interpretive zone standards were selected by correlating zone diameters with MICs by using both regression analysis (method of least squares) and the error-rate bounding method described by Metzler and DeHaan (8) .
Isolates typical of current clinical strains were obtained from the stock culture collection at the Clinical Microbiology Institute. The strains were stored at -60°C or below until processed. The 350 isolates are listed in Table 2 . Regression analysis compared levofloxacin MICs with ofloxacin MICs. The regression formula was y = 0.97 -0.6 x, where y = the MIC of levofloxacin (micrograms per milliliter as log2 + 9) and x = the MIC of ofloxacin (micrograms per milliliter as log2 + 9). The correlation coefficient was 0.98. Although the two drugs differed in their in vitro potencies, their spectra of activity were very nearly identical. In vitro MIC tests with one drug may be used to predict susceptibility or resistance to the other.
The results of in vitro studies with levofloxacin are summarized in Table 2 . Levofloxacin was less active against Serratia marcescens and Providencia stuartii (geometric mean MICs, 1.1 and 1.6 ,ug/ml, respectively) than it was against the other enteric bacilli and Acinetobacter calcoaceticus (geometric mean MICs, 0.06 to 0.33 ug/Iml). Likewise, mean MICs were generally higher for Xanthomonas maltophilia (geometric mean MIC, 1.4 ,ug/ml) and the pseudomonads (geometric mean MICs, 0.11 to 2.4 ,ug/ml). Staphylococci, including methicillin-resistant strains, were very susceptible to levofloxacin (geometric mean MICs, 0.17 to 0.20 p,g/ml); however, ciprofloxacin-resistant strains of Staphylococcus aureus were also relatively resistant to levofloxacin (geometric mean MIC, 8.0 ,ug/ml). For the enterococci Listeria monocytogenes and Streptococcus pneumoniae, mean MICs were two to four times higher than those for other Streptococcus spp. (0.93 to 1.9 versus 0.5 lag/ml). Table 2 also describes the range of zone diameters with 5-and 10-p,g levofloxacin disks. The average zone around 10-kug disks was 27 mm (6 to 40 mm), whereas the zones around 5-,ug disks averaged 24 mm (6 to 36 mm). With the majority of strains, there was a 2-to 4-mm difference in the zone size for the two disk potencies. Unusually large zone sizes were uncommon, i.e., 95% of the zones around 5-,ug disks were <31 mm in diameter, and with 10-,g disks, 96% of the strains gave zones of 534 mm. These data were also examined to evaluate the abilities of the two disks to discriminate between resistant and susceptible populations. (1, 5, 6) . Previous studies have recommended the use of 5-,ug disks and interpretive criteria of .12 mm for resistance and .16 mm for susceptibility for ofloxacin (5, 6) . Because levofloxacin and ofloxacin have very similar spectra of activity (2) (3) (4) (5) (6) (11) (12) (13) , it seems reasonable to select the same disk potency for both agents. Identical zone size interpretive criteria apply to both disks. If pharmacokinetic and clinical data support the use of higher MIC breakpoints for levofloxacin, a 10-,ug disk might be advantageous; however, such a modification of MIC breakpoints is not likely to occur in the near future.
NOTES
In summary, we recommend that a 5-,ug levofloxacin disk be used with zone breakpoints of < 12 mm for resistance and .16 mm for susceptibility. A 10-,ug levofloxacin disk with appropriately adjusted zone size breakpoints would also perform satisfactorily, but at this time there is no obvious reason to consider use of the more potent disk.
